Clinical application of novel urinary biomarkers for avoiding acute renal injury by platinum anti -cancer drugs

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K06662
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: University of Yamanashi (2023); Chiba University (2021-2022)
• Principal Investigator: Suzuki Takaaki 山梨大学, 大学院総合研究部, 特任教授 (30396676)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: L-FABP / 腎障害 / プラチナ系抗がん薬

Outline of Final Research Achievements

Urinary L-FABP (Liver type fatty acid binding protein) is considered an indicator reflecting oxidative stress in the proximal tubules and a candidate marker for early detection of renal function changes. In this study, we focused on L-FABP.
Urine samples were collected from 14 patients during 17 sessions of chemotherapy, and L-FABP levels were measured. Although there was significant variability among patients, it was found that the higher the L-FABP levels at the start of chemotherapy, the greater the subsequent increase in L-FABP levels, providing a clinical application insight. It is necessary to increase the number of samples for further investigation.

Free Research Field

医療薬学

Academic Significance and Societal Importance of the Research Achievements

本研究により尿中L-FABP値はプラチナ系抗がん剤による腎障害の予測に有用なバイオマーカーか検証することができ、有用な場合はプラチナ系抗がん剤の治療継続と安全性向上に寄与できると考えられる。